NCT05963945

Brief Summary

The primary objective is to evaluate the performance parameters of the proposed DLAD (Carebot AI CXR) in comparison to individual radiologists.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
956

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 18, 2022

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 17, 2022

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 21, 2023

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 12, 2023

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 27, 2023

Completed
Last Updated

July 27, 2023

Status Verified

July 1, 2023

Enrollment Period

1 month

First QC Date

July 12, 2023

Last Update Submit

July 19, 2023

Conditions

Keywords

Artificial IntelligenceComputer-Aided DetectionDeep LearningChest X-rayRadiology

Outcome Measures

Primary Outcomes (1)

  • Performance test

    The primary objective is to evaluate the performance parameters of the proposed DLAD (Carebot AI CXR) in comparison to individual radiologists. The performance test includes sensitivity and specificity, positive and negative likelihood ratio, and positive and negative predictive value. The aforementioned parameters are statistically compared using confidence intervals (CI) and p-Values. The comparison procedure consists of two steps: a global hypothesis test is conducted to determine whether there are significant differences between DLAD and radiologists. If the global hypothesis test yields a significant result, individual hypothesis tests are performed. Additionally, multiple comparison methods, such as McNemar with continuity correction for Se and Sp, Holm method for LRs, and weighted generalized score statistics for PVs, are applied to control the overall error rate. All tests are performed as two-tailed tests at the 5% significance level.

    March 2023

Study Arms (1)

Retrospective collection for the period October 18th, 2022, and November 17th, 2022

A total of 1,073 chest X-rays were acquired within the specified period at the department. The data collection remained intact and unaffected throughout the testing phase, ensuring the integrity of the dataset. The collected sample accurately represents the prevalence of findings within the observed population. After excluding ineligible studies such as X-rays from patients under 18 years of age, lateral projection X-rays, and scans of insufficient quality, a total of 956 relevant CXRs were identified for further assessment.

Device: Carebot AI CXR

Interventions

The proposed DLAD (Carebot AI CXR) is a deep learning-based medical device designed to assist radiologists in interpreting chest X-ray images acquired in anteroposterior (AP) or posteroanterior (PA) projection. By employing advanced deep learning algorithms, this solution enables automatic detection of abnormal findings by analyzing visual patterns associated with specific conditions. The targeted abnormalities include atelectasis (ATE), consolidation (CON), pleural effusion (EFF), pulmonary lesion (LES), subcutaneous emphysema (SCE), cardiomegaly (CMG), and pneumothorax (PNO). The DLAD functions as a prediction algorithm complemented by various application peripherals, such as web-based communication tools, DICOM file conversion capabilities, and storage and reporting libraries supporting both DICOM Structured Report and DICOM Presentation State formats.

Retrospective collection for the period October 18th, 2022, and November 17th, 2022

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient's Sex Female: 480 (50.21 %) Male: 474 (49.58 %) Unspecified: 2 (0.21 %) Patient's Age 18-30: 58 (6.07 %) 31-50: 163 (17.05 %) 51-70: 366 38.28 %) 70+: 369 (38.60 %)

You may qualify if:

  • Hospital patients \> 18 years who were referred for chest radiography October 18th, 2022, and November 17th, 2022 at the Radiodiagnostic Department of the Havířov Hospital, p.o.

You may not qualify if:

  • Patients \< 18 years
  • Chest X-ray images in lateral positions
  • Duplicated chest X-ray images

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nemocnice Havířov, p. o.

Havířov, 73601, Czechia

Location

Related Publications (1)

  • KVAK, Daniel, Anna CHROMCOVÁ, Petra OVESNÁ, Jakub DANDÁR, Marek BIROŠ, Robert HRUBÝ, Daniel DUFEK a Marija PAJDAKOVIĆ. Can Deep Learning Reliably Recognize Abnormality Patterns on Chest X-rays? A Multi-Reader Study Examining One Month of AI Implementation in Everyday Radiology Clinical Practice. arXiv. 2023, 2305.10116, 26 s.

    RESULT

MeSH Terms

Conditions

PneumothoraxSolitary Pulmonary NodulePulmonary AtelectasisSubcutaneous EmphysemaCardiomegalyPleural Effusion

Condition Hierarchy (Ancestors)

Pleural DiseasesRespiratory Tract DiseasesLung DiseasesEmphysemaPathologic ProcessesPathological Conditions, Signs and SymptomsHeart DiseasesCardiovascular DiseasesHypertrophyPathological Conditions, Anatomical

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 12, 2023

First Posted

July 27, 2023

Study Start

October 18, 2022

Primary Completion

November 17, 2022

Study Completion

March 21, 2023

Last Updated

July 27, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Locations